BerGenBio ASA (OSL:BGBIO) Other Gross PPE : kr1.25 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Other Gross PPE?

BerGenBio ASA's Other Gross PPE for the quarter that ended in Dec. 2024 was kr1.25 Mil.

BerGenBio ASA's quarterly Other Gross PPE declined from Jun. 2024 (kr0.22 Mil) to Sep. 2024 (kr0.12 Mil) but then increased from Sep. 2024 (kr0.12 Mil) to Dec. 2024 (kr1.25 Mil).

BerGenBio ASA's annual Other Gross PPE stayed the same from Dec. 2022 (kr0.00 Mil) to Dec. 2023 (kr0.00 Mil) but then increased from Dec. 2023 (kr0.00 Mil) to Dec. 2024 (kr1.25 Mil).

BerGenBio ASA Other Gross PPE Historical Data

The historical data trend for BerGenBio ASA's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Other Gross PPE Chart

BerGenBio ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Gross PPE

Get a 7-Day Free Trial

1.63

1.25

BerGenBio ASA Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															-	0.33	0.22	0.12	1.25

BerGenBio ASA Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

BerGenBio ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

0RU5:UK 7BG0:Germany

Address

Mollendalsbakken 9, Bergen, NOR, 5009

Website

https://www.bergenbio.com

BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.

BerGenBio ASA Headlines

No Headlines